MBAI
Check-Cap Ltd.
Healthcare — Diagnostics & Research
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.
None
$3.12
$-0.42 (-11.73%)
Price History
52-Week Range
Sign in to add MBAI to a watchlist or set price alerts.
Fundamentals
| Market Cap | $9.59M |
| P/E Ratio (TTM) | 1.88 |
| Forward P/E | - |
| EPS (TTM) | $0.66 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | 416.71% |
| Debt/Equity | 0.47 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 44.3 |
| Beta | 0.76 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.92 |
| 52-Week Low | $0.59 |
| 50-Day Avg | $1.52 |
| 200-Day Avg | $1.71 |
| Avg Volume | 129.8K |
| Volume | 19.9K |
Performance Analysis
BULLISHMBAI shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 76% of its 52-week range.
~
RSI at 44.3 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
P/E of 1.9 suggests the stock may be undervalued.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report